TNGX

Tango Therapeutics, Inc. (TNGX) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Tango Therapeutics, Inc. is a precision oncology company focused on developing novel small molecules for genetically defined cancers. The company has no products approved for commercial sale and has not generated revenue from product sales. It operates as a non-accelerated filer and a smaller reporting company.

Key Financial Metrics

Note: Cash, cash equivalents, and marketable securities are derived from the Balance Sheet (Cash $157,828 + Marketable Securities $222,011).

Material Changes vs. Prior Period

• Revenue: Collaboration revenue dropped to $0 from $5.4 million in Q1 2025. This is due to the truncation of the research term in the Gilead collaboration agreement in August 2025, which resulted in the recognition of all remaining deferred revenue ($53.8 million) in Q3 2025.
• Net Loss: Net loss increased by $5.6 million to $45.5 million, primarily driven by the loss of collaboration revenue and increased General and Administrative (G&A) expenses.
• Operating Expenses:
  • R&D: Decreased by $2.9 million to $33.5 million. This was driven by the discontinuation of the TNG908 clinical program and lower discovery costs, partially offset by increased spending on the vopimetostat and TNG456 programs.
  • G&A: Increased by $3.8 million to $15.2 million, primarily due to higher personnel-related costs and stock-based compensation.
• Liquidity: Cash and marketable securities increased significantly to $379.8 million, bolstered by $64.4 million in gross proceeds from an "at-the-market" stock offering program during the quarter.

Guidance, Outlook, and Risks

Outlook and Milestones:

• Cash Runway: Management expects existing cash, cash equivalents, and marketable securities ($379.8 million) to fund operations into 2028.
• Clinical Updates: The company plans to disclose initial Phase 1/2 safety and efficacy data for the vopimetostat combination trial, lung cancer cohort data for vopimetostat monotherapy, and initial data for the TNG456 Phase 1/2 trial in 2026.
• New Trials: A Phase 1/2 combination trial of vopimetostat and ERAS-0015 (from Erasca, Inc.) is planned for initiation in the second half of 2026.
• Portfolio Prioritization: The company is deprioritizing TNG260 (CoREST inhibitor) due to limited clinical benefit and has no current plans to advance TNG961.

Risks and Contingencies:

• Capital Needs: The company anticipates continuing to incur significant losses and will need substantial additional funding to advance clinical programs.
• Supply Chain: The company relies on a single source (an affiliate of WuXi AppTec) for the active pharmaceutical ingredients (API) for all clinical-stage candidates. Proposed Congressional legislation could restrict business with this supplier.
• Development Risk: No products are approved; clinical trials may fail to demonstrate safety or efficacy, and regulatory approval is uncertain.

Investor Verification Checklist

• Revenue Sustainability: Verify the timeline for future revenue generation given the cessation of Gilead collaboration revenue.
• Cash Burn Rate: Confirm the accuracy of the "into 2028" cash runway estimate against current quarterly burn rates (~$44M operating cash outflow).
• Supply Chain Resilience: Assess the impact of potential U.S. legislation restricting WuXi AppTec on the company's ability to manufacture clinical supplies.
• Clinical Data Readiness: Monitor the timing and quality of the anticipated 2026 data readouts for vopimetostat and TNG456.
• Equity Dilution: Track the remaining capacity under the Leerink "at-the-market" sales agreement ($100M total, with ~$35.6M remaining after Q1 2026 sales).